|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Biomarkers of aging显示文摘Aging biomarkers are a combination of biological parameters to(i)assess age-related changes,(ii)track the physiological aging process,and(iii)predict the transition into a pathological status.Although a broad spectrum of aging biomarkers has been developed,their potential uses and limitations remain poorly characterized.An immediate goal of biomarkers is to help us answer the following three fundamental questions in aging research:How old are we?Why do we get old?And how can we age slower?This review aims to address this need.Here,we summarize our current knowledge of biomarkers developed for cellular,organ,and organismal levels of aging,comprising six pillars:physiological characteristics,medical imaging,histological features,cellular alterations,molecular changes,and secretory factors.To fulfill all these requisites,we propose that aging biomarkers should qualify for being specific,systemic,and clinically relevant. | Aging Biomarker Consortium Hainan Bao Jiani Cao Mengting Chen Min Chen Wei Chen Xiao Chen Yanhao Chen Yu Chen Yutian Chen Zhiyang Chen Jagadish K Chhetri Yingjie Ding Junlin Feng Jun Guo Mengmeng Guo Chuting He Yujuan Jia Haiping Jiang Ying Jing Dingfeng Li Jiaming Li Jingyi Li Qinhao Liang Rui Liang Feng Liu Xiaoqian Liu Zuojun Liu Oscar Junhong Luo Jianwei Lv Jingyi Ma Kehang Mao Jiawei Nie Xinhua Qiao Xinpei Sun Xiaoqiang Tang Jianfang Wang Qiaoran Wang Siyuan Wang Xuan Wang Yaning Wang Yuhan Wang Rimo Wu Kai Xia Fu-Hui Xiao Lingyan Xu Yingying Xu Haoteng Yan Liang Yang Ruici Yang Yuanxin Yang Yilin Ying Le Zhang Weiwei Zhang Wenwan Zhang Xing Zhang Zhuo Zhang Min Zhou Rui Zhou Qingchen Zhu Zhengmao Zhu Feng Cao Zhongwei Cao Piu Chan Chang Chen Guobing Chen Hou-Zao Chen Jun Chen Weimin Ci Bi-Sen Ding Qiurong Ding Feng Gao Jing-Dong JHan Kai Huang Zhenyu Ju Qing-Peng Kong Ji Li Jian Li Xin Li Baohua Liu Feng Liu Lin Liu Qiang Liu Qiang Liu Xingguo Liu Yong Liu Xianghang Luo Shuai Ma Xinran Ma Zhiyong Mao Jing Nie Yaojin Peng Jing Qu Jie Ren Ruibao Ren Moshi Song Zhou Songyang Yi Eve Sun Yu Sun Mei Tian Shusen Wang Si Wang Xia Wang Xiaoning Wang Yan-Jiang Wang Yunfang Wang Catherine CL Wong Andy Peng Xiang Yichuan Xiao Zhengwei Xie Daichao Xu Jing Ye Rui Yue Cuntai Zhang Hongbo Zhang Liang Zhang Weiqi Zhang Yong Zhang Yun-Wu Zhang Zhuohua Zhang Tongbiao Zhao Yuzheng Zhao Dahai Zhu Weiguo Zou Gang Pei Guang-Hui Liu | 2023 | Science China(Life Sciences)2023，66，5： | 2 |
| 2 | Underestimated contribution of fugitive emission to VOCs in pharmaceutical industry based on pollution characteristics, odorous activity and health risk assessment显示文摘Fugitive emission has been becoming an important source of volatile organic compounds(VOCs) in pharmaceutical industry,but the exact contribution of fugitive emission remains incompletely understood.In present study,pollution characteristics,odorous activity and health risk of stack and fugitive emissions of VOCs from four functional units (e.g.,workshop,sewage treatment station,raw material storage and hazardous waste storage) of three representative pharmaceutical factories were investigated.Workshop was the dominant contributor to VOCs of fugitive emission in comparison with other functional units.Extreme high concentration of VOCs from fugitive emission in unsealed workshop (94.87 mg/m^(3))was observed relative to sealed one (1.18 mg/m^(3)),accounting for 31%and 5%of total VOCs,respectively.Fugitive emission of VOCs in the unsealed workshop mainly consisted of nhexane,1-hexene and dichloromethane.Odorous activity indexes and non-cancer hazard ratios of these VOCs from fugitive emission in the unsealed workshop were as high as that from stack exhaust.Furthermore,cancer risk of dichloromethane from fugitive emission and stack exhaust was up to (1.6-1.8)×10^(-5).Odorous activity or health risk index of the VOCs from fugitive emission was up to 13 or 11 times of the corresponding threshold value,posing remarkable health threat on pharmaceutical workers.Our?ndings highlighted the possibly underestimated contribution of fugitive emission on VOCs in the pharmaceutical industry. | Qinhao Lin Zhong Gao Weikun Zhu Jiangyao Chen Taicheng An | 2023 | Journal of Environmental Sciences2023，，4： | 1 |
| 3 | Atmospheric VOCs in an industrial coking facility and the surrounding area:Characteristics,spatial distribution and source apportionment显示文摘Industrial coking facilities are an important emission source for volatile organic compounds(VOCs).This study analyzed the atmospheric VOC characteristics within an industrial coking facility and its surrounding environment.Average concentrations of total VOCs(TVOCs)in the surrounding residential activity areas(R1 and R2),the coking facility(CF)and the control area(CA)were determined to be 138.5,47.8,550.0,and 15.0μg/m^(3),respectively.The cold drum process and coking and quenching areas within the coking facility were identified as the main polluting processes.The spatial variation in VOCs composition was analyzed,showing that VOCs in the coking facility and surrounding areas were mainly dominated by aromatic compounds such as BTX(benzene,toluene,and xylenes)and naphthalene,with concentrations being negatively correlated with the distance from the coking facility(p<0.01).The sources of VOCs in different functional areas across the monitoring area were analyzed,finding that coking emissions accounted for 73.5%,33.3% and 27.7% of TVOCs in CF,R1 and R2,respectively.These results demonstrated that coking emissions had a significant impact on VOC concentrations in the areas surrounding coking facility.This study evaluates the spatial variation in exposure to VOCs,providing important information for the influence of VOCs concentration posed by coking facility to surrounding residents and the development of strategies for VOC abatement. | Meicheng Wen Weiqiang Deng Jin Huang Shu Zhang Qinhao Lin ChaoWang Shengtao Ma Wanjun Wang Xin Zhang Guiying Li Taicheng An | 2024 | Journal of Environmental Sciences2024，，4： | 0 |
| 4 | MIIP inhibits clear cell renal cell carcinoma proliferation and angiogenesis via negative modulation of the HIF-2α-CYR61 axis显示文摘Objective:In various cancers,migration and invasion inhibitory protein(MIIP)is expressed at low level and is involved in cancer pathogenesis.Herein,we sought to explore the function of MIIP in clear cell renal cell carcinoma(ccRCC).Methods:CCK-8,colony formation,cell cycle,and endothelial cell tube formation assays were performed to evaluate the roles of MIIP in ccRCC proliferation and angiogenesis.To explore the underlyi ng mechanism,we con ducted RNA-sequencing,GSEA,qRT-PCR,Western blot,ELISA,cell transfection,coimmunoprecipitation,and ubiquitination assays in ccRCC cell lines.Furthermore,xenograft tumor growth in nude mice,and Ki-67 and CD31 staining in xenograft tissues were examined.Finally,the association of MIIP expression with clinical pathology and the expression status of HIF-2a and cysteine-rich 61(CYR61)were further analyzed in human RCC tissues through Western blot and immunohistochemistry.Results:Both in vitro and in vivo functional experiments indicated that forced expression of MIIP inhibited ccRCC proliferation and angiogenesis,whereas silencing MIIP either in normal HK-2 cells or in ccRCC cells had the opposite effect(P<0.05).Mechanistically,CYR61 was identified as a gene significantly downregulated by MIIP overexpression,and was required for the suppressive role of MIIP in ccRCC.MIIP was found to promote HSP90 acetylation and thus impair its chaperone function toward HIF-2a.Consequently,RACK1 binds HIF-2a and causes its ubiquitination and proteasomal degradation,thus decreasing the transcription of its target,CYR61.Finally,analyses of clinical samples demonstrated that MIIP is significantly downregulated in cancer vs.normal tissues in RCC cases,and its expression is negatively associated with histological grade,metastasis,the prognosis of patients with RCC,and the expression of HIF-2a and CYR61(P<0.05).Conclusions:MIIP is a novel tumor suppressor in ccRCC via negative regulation of HIF-2a-CYR61 axis. | Fengqi Yan Qinhao Wang Mingyuan Xia Yi Ru Wei Hu Guang Yan Xin Xiong Mei Zhang Jiancai Wang Qi Li Bo Zhang He Wang Wei Lin Guojun Wu Xia Li | 2022 | Cancer Biology & Medicine2022，19，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员